

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1-92. (Canceled).

93. (Currently amended) A pharmaceutical composition comprising a synergistic combination~~therapeutically effective amount~~ of at least one chemotherapeutic agent and at least one immunoconjugate; wherein the immunoconjugate comprises at least one maytansinoid compound linked to a monoclonal antibody or fragment thereof; and wherein the monoclonal antibody or fragment thereof binds to an antigen expressed by a cancer cell.

94. (Previously presented) The pharmaceutical composition of claim 93, wherein the chemotherapeutic agent is a taxane compound, an epothilone compound, a platinum compound, an epipodophyllotoxin compound, a camptothecin compound, or a mixture of two or more thereof.

95. (Previously presented) The pharmaceutical composition of claim 93, wherein the chemotherapeutic agent is a taxane compound, a platinum compound, an epipodophyllotoxin compound, a camptothecin compound, or a mixture of two or more thereof.

96. (Previously presented) The pharmaceutical composition of claim 93, wherein the chemotherapeutic agent is paclitaxel, docetaxel, epothilone A, epothilone B, epothilone C, epothilone D, epothilone E, epothilone F, cisplatin, carboplatin, oxaliplatin, iproplatin, ormaplatin, tetraplatin, etoposide, teniposide, camptothecin, topotecan, irinotecan, 9-aminocamptothecin, or a mixture of two or more thereof.

97. (Previously presented) The pharmaceutical composition of claim 93, wherein the chemotherapeutic agent is paclitaxel, cisplatin, etoposide, docetaxel, topotecan, or a mixture of two or more thereof.


98. (Previously presented) The pharmaceutical composition of claim 93, wherein the monoclonal antibody or fragment thereof binds to a CD56 antigen.

99. (Previously presented) The pharmaceutical composition of claim 93, wherein the monoclonal antibody or fragment thereof is at least one of Fv, Fab, Fab' or F(ab')<sub>2</sub>.

100. (Previously presented) The pharmaceutical composition of claim 93, wherein the monoclonal antibody or fragment thereof is humanized N901.

101. (Previously presented) The pharmaceutical composition of claim 93, wherein the monoclonal antibody or fragment thereof is humanized C242.

102. (Previously presented) The pharmaceutical composition of claim 93, wherein the immunoconjugate comprises at least one maytansinoid compound of formula (IV):




wherein is  $Z_0$  is H or SR; R is methyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl or heterocyclic; t is 1, 2 or 3;  $Y_0$  is chlorine or hydrogen; and  $X_3$  is hydrogen or methyl.

103. (Previously presented) The pharmaceutical composition of claim 102, wherein  $Z_0$  is H; t is 2;  $Y_0$  is chlorine; and  $X_3$  is methyl.

104. (Previously presented) The pharmaceutical composition of claim 93, wherein the immunoconjugate is of the formula:


Amendment under 37 C.F.R. § 1.111  
USSN 09/671,995



wherein MAb is a monoclonal antibody or fragment thereof that binds to an antigen expressed by the cancer cell.

105. (Previously presented) A pharmaceutical composition comprising a synergistic combination of at least one chemotherapeutic agent and at least one immunoconjugate; wherein the chemotherapeutic agent is a taxane compound, an epothilone compound, a platinum compound, an epipodophyllotoxin compound, a camptothecin compound, or a mixture of two or more thereof; and wherein the immunoconjugate is:

Amendment under 37 C.F.R. § 1.111  
USSN 09/671,995




wherein MAb is a monoclonal antibody or fragment thereof that binds to an antigen expressed by a cancer cell.

106-143. (Canceled)

144. (Currently amended) A pharmaceutical composition comprising a synergistic combination ~~therapeutically effective amount~~ of (i) at least one chemotherapeutic agent selected from the group consisting of paclitaxel, docetaxel, cisplatin, etoposide, topotecan and irinotecan and (ii) an immunoconjugate comprising a maytansinoid and a humanized monoclonal antibody selected from the group consisting of N901 and C242.

145. (Previously presented) The pharmaceutical composition of claim 144, wherein the maytansinoid is a compound of formula (IV):

Amendment under 37 C.F.R. § 1.111  
USSN 09/671,995




wherein  $Z_0$  is H or SR; wherein R is methyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl or heterocyclic; t is 1, 2 or 3;  $Y_0$  is chlorine or hydrogen; and  $X_3$  is hydrogen or methyl.

146-147. (canceled)

148. (Currently amended) A pharmaceutical composition comprising a synergistic combination therapeutically effective amount of (i) at least one chemotherapeutic agent selected from the group consisting of paclitaxel, docetaxel, cisplatin, etoposide, topotecan and irinotecan and (ii) an immunoconjugate comprising a maytansinoid and a humanized monoclonal antibody or fragment thereof that binds to an antigen expressed by a small cell lung cancer cell, a non small cell lung cancer cell or a colorectal cancer cell.

Amendment under 37 C.F.R. § 1.111  
USSN 09/671,995

149. (Previously presented) The pharmaceutical composition of claim 148, wherein the maytansinoid is a compound of formula (IV):



wherein  $Z_0$  is H or SR; wherein R is methyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl or heterocyclic; t is 1, 2 or 3;  $Y_0$  is chlorine or hydrogen; and  $X_3$  is hydrogen or methyl.

150-151. (Canceled)